I. Jacobson

发表

Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C

I. Jacobson, M. Gambarin-Gelwan, I. Jacobson, 2008, Journal of viral hepatitis.

Randomized trial of albinterferon alfa‐2b every 4 weeks for chronic hepatitis C virus genotype 2/3

P. Komolmit, S. Zeuzem, G. Feutren, 2012, Journal of viral hepatitis.

Antiviral response and resistance analysis of treatment‐naïve HCV‐infected patients receiving single and multiple doses of GS‐9190

H. Mo, M. D. Miller, D. Brainard, 2016, Journal of viral hepatitis.

Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin

M. King, P. Ferenci, E. Gane, 2017, Journal of viral hepatitis.

Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin

S. Sarin, P. Komolmit, K. Brown, 2013, Journal of viral hepatitis.

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C

J. Pawlotsky, X. Forns, G. Dusheiko, 2012, Journal of viral hepatitis.

Clinical predictors of response to recombinant interferon‐α treatment in patients with chronic non‐A, non‐B hepatitis (hepatitis C)

E. Schiff, J. Albrecht, G. Davis, 1994 .

Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection

R. Liu, L. Chiriboga, H. Yee, 2009, Journal of viral hepatitis.

Hepatic inflammatory cytokine mRNA expression in hepatitis C virus–human immunodeficiency virus co‐infection

S. Chung, M. Fiel, A. Talal, 2008, Journal of viral hepatitis.

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies

X. Forns, S. Zeuzem, S. Ouwerkerk-Mahadevan, 2015, Journal of viral hepatitis.

Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection

E. Schiff, T. Hassanein, D. Dieterich, 2020 .

Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C – authors' reply

A. Talal, I. Jacobson, E. Korner, 2013, Alimentary pharmacology & therapeutics.